Browse the evidence

Serotonin (5-HT) released from enterochromaffin (EC) cells modulates visceral sensitivity and pain signaling via direct synaptic interaction with nociceptive neurons.

If you have IBS or chronic gut pain, your gut cells (EC cells) might be sending too many pain signals to your brain using serotonin. Blocking these signals (with specific antagonists) can reduce pain and anxiety, showing that gut pain is a neurological issue, not just inflammation.

Short-term high-fat diet induces DNA hypermethylation and alters gene expression of PYGM (glycogen phosphorylase, muscle), an adaptive epigenetic response to glycogen depletion, which is preserved by resistance exercise.

When you switch to a low-carb/high-fat diet, your body epigenetically silences the gene responsible for breaking down glycogen (PYGM) because you aren't eating carbs. This is a smart adaptation. Exercise helps maintain this state but doesn't change this specific epigenetic switch.

Tirzepatide treatment is not significantly associated with an increased risk of pancreatitis compared to control groups (placebo, basal insulin, or GLP-1 RAs) in patients with type 2 diabetes and obesity.

If you have Type 2 Diabetes or Obesity and are considering Tirzepatide, current data from multiple clinical trials suggests it does not significantly increase your risk of pancreatitis compared to other common diabetes or weight-loss medications. This is reassuring news if you were avoiding the drug due to fears of pancreatic inflammation.

Tirzepatide is associated with a significantly increased risk of composite gallbladder or biliary diseases (including cholelithiasis, cholecystitis, and other gallbladder disorders) compared to placebo or basal insulin, but not compared to GLP-1 RAs.

Tirzepatide increases the risk of gallbladder or biliary issues (like gallstones or inflammation) compared to placebos or insulin. However, this risk appears similar to other GLP-1 medications. Be aware of symptoms like abdominal pain and report them to your doctor promptly, as early detection is key.

Use of GLP-1 receptor agonists (GLP1-RAs) is not associated with an increased risk of thyroid cancer compared to DPP-4 inhibitors in patients with type 2 diabetes.

If you have type 2 diabetes and are considering a GLP-1 medication like Ozempic or Wegovy, current large-scale evidence suggests it does not increase your risk of thyroid cancer compared to other common diabetes drugs. While rodent studies showed thyroid effects, this has not been observed in human population studies.

AMPK activation inhibits ribosome biogenesis by blocking mTORC1 signaling, while mTORC1 signaling may negatively affect mitochondrial biogenesis, creating a molecular competition.

This is a molecular detail. For training, it means high-energy demand (endurance) signals the body to build mitochondria, potentially suppressing the signal to build protein (muscle) if not managed.

Administration of the ketone metabolite BHB-Phe (N-beta-hydroxybutyryl phenylalanine) suppresses food intake and reduces body weight in obese mice.

This research identifies a specific metabolite, BHB-Phe, which is naturally produced during ketosis and actively suppresses hunger. While the study used high-dose injections in obese mice, it suggests that maintaining ketosis may naturally elevate this compound, contributing to reduced food intake. For now, this is a mechanistic insight rather than a direct supplement recommendation, as oral bioavailability and dosing in humans are not established.

GLP-1 receptor agonists delay gastric emptying, increasing the risk of aspiration during anesthesia, necessitating specific preoperative discontinuation guidelines.

If you take Ozempic and have surgery, tell your surgeon. You likely need to stop the drug 1-7 days before surgery to prevent vomiting during anesthesia. Follow your doctor's specific instructions.

Dapagliflozin (SGLT2 inhibitor) lowers systolic blood pressure through an initial plasma volume contraction followed by a sustained reduction in sympathetic nervous system activity.

If you have type 2 diabetes and high blood pressure, dapagliflozin 10mg daily can help lower your blood pressure. It works by initially reducing blood volume and, over time, by calming the nervous system's stress response on your blood vessels. This happens even after the initial fluid loss stops.

Combining Dapagliflozin and Exenatide results in a synergistic blood pressure reduction that exceeds the sum of their individual effects, driven by plasma volume contraction and potentially other mechanisms beyond SNS reduction.

For patients with type 2 diabetes and obesity, combining dapagliflozin and exenatide offers a stronger blood pressure reduction than using either drug alone. This synergy helps achieve better cardiovascular protection, though the exact mechanism beyond fluid loss is still being studied.

Exenatide (GLP-1 RA) reduces parasympathetic nervous system activity, which may contribute to an increase in heart rate, but does not significantly lower systolic blood pressure on its own in this population.

Exenatide alone may not significantly lower blood pressure in people with type 2 diabetes and obesity, but it does reduce parasympathetic nervous system activity, which can increase heart rate. It is often used in combination with other drugs for better cardiovascular outcomes.

Tirzepatide does not increase the risk of major adverse cardiovascular events (MACEs) in patients with type 2 diabetes.

Tirzepatide does not increase the risk of major adverse cardiovascular events (MACEs) in patients with type 2 diabetes. This makes it a safe option for cardiovascular risk management.

SGLT2 inhibitors and GLP-1 receptor agonists reduce arrhythmia risk in diabetic patients by ameliorating intracellular sodium and calcium dysregulation and reducing fibrosis.

If you have type 2 diabetes, ask your doctor about SGLT2 inhibitors or GLP-1 agonists. These drugs do more than lower blood sugar; they help stabilize the electrical activity of your heart and reduce scarring, lowering your risk of sudden cardiac death.

Deletion of the p38α kinase in adipose tissue protects against high-fat diet-induced obesity by increasing energy expenditure and brown adipose tissue (BAT) thermogenesis.

Current research suggests that low levels of the p38α protein in fat tissue are associated with higher body mass index in humans. In mice, removing p38α from fat cells prevents obesity by boosting heat production. This implies that therapies aiming to reduce p38α activity in fat might help treat obesity, but this is currently only a mechanistic finding in animals, not a human treatment protocol.

The p38δ kinase isoform promotes brown adipose tissue thermogenesis, and its deletion leads to obesity and reduced energy expenditure.

In mice, the p38δ protein is required for fat-burning. Removing it causes obesity. This suggests that maintaining or activating p38δ in fat tissue could be a potential strategy to prevent obesity, though no human treatments exist yet.

Older anti-obesity medications (Orlistat, Sibutramine, Phentermine, Naltrexone/Bupropion, Phentermine/Topiramate) achieve mean weight loss between 5-10%, which is often insufficient to meet patient expectations and leads to lower long-term adherence.

Older anti-obesity medications (like Orlistat, Sibutramine, and combination drugs) typically produce 5-10% weight loss, which is beneficial but often fails to meet patient expectations, leading to higher discontinuation rates compared to newer agents.

Semaglutide is associated with an increased incidence of neoplasms (cancer) in clinical trials, specifically involving the thyroid, bladder, colorectal, and pancreas, although the absolute number of cases is often low and causality is not conclusive.

If you are taking semaglutide (Ozempic/Wegovy), be aware that clinical trials showed a small number of cancer cases, particularly in the thyroid, bladder, and pancreas. However, the paper notes this is not conclusive proof that the drug causes cancer, as obesity and diabetes themselves increase cancer risk. You should discuss your personal risk factors (especially family history of thyroid cancer) with your doctor.

Protein hydrolysates do not provide superior muscle protein synthesis (MPS) or anabolic properties compared to intact non-hydrolysed proteins or free amino acids.

If you are taking protein hydrolysates expecting better muscle growth than regular protein, you are likely wasting money. Current evidence shows that intact proteins (like whey isolate or casein) and free amino acids are just as effective for muscle recovery and adaptation. Stick to cost-effective, intact protein sources unless you have specific digestive issues.

Diet-induced weight loss in obese individuals with or without type 2 diabetes significantly increases plasma Lipoprotein(a) [Lp(a)] levels, potentially antagonizing the cardiovascular benefits of conventional risk factor improvement.

If you are obese and have type 2 diabetes, losing weight through diet will likely improve your blood sugar and cholesterol, but it may also raise your Lipoprotein(a) levels. This rise is a known biological response to calorie restriction in this population and might partially cancel out the heart benefits of weight loss. You should still lose weight, but discuss monitoring your Lp(a) levels with your doctor to see if additional interventions are needed.

GLP-1 receptor agonists (GLP-1RAs) cause a significantly higher rate of intolerable gastrointestinal adverse reactions leading to drug withdrawal compared to other hypoglycemic agents (Insulin, SGLT2i, DPP4i, TZD) and placebo.

If you are considering a GLP-1RA, expect a higher likelihood of gastrointestinal side effects (nausea, vomiting, diarrhea) compared to other common diabetes drugs like Metformin or SGLT2 inhibitors. These side effects are the most common reason for stopping the medication. However, not all GLP-1RAs carry the same risk; Dulaglutide appears to have the lowest risk of intolerable GI reactions, while Semaglutide and Liraglutide have higher risks, especially at higher doses.

Leptin analogs (metreleptin) are effective for treating obesity only in patients with generalized lipodystrophy or congenital leptin deficiency, but are ineffective and contraindicated for general diet-based obesity due to leptin resistance.

Leptin analogs like metreleptin are not for general weight loss. They are reserved for rare genetic conditions like generalized lipodystrophy where the body cannot produce leptin. For most people with obesity, leptin levels are already high, and adding more does not help.

MC4R agonists (setmelanotide) are effective for treating obesity in individuals with specific genetic deficiencies (POMC, PCSK1, LEPR) or Bardet-Biedl syndrome, but are not approved for general obesity.

If you have a rare genetic condition like POMC deficiency or Bardet-Biedl syndrome, ask your doctor about setmelanotide. It is a daily injection approved for these specific conditions. It is not approved for general obesity.

The association between ultra-processed food consumption and colorectal cancer risk is significant in men but not in women, and there is no significant association with prostate, rectal, pancreatic, or central nervous system cancers.

If you are male, be particularly mindful of UPF intake as it is linked to a higher risk of colorectal cancer. For women, the link to colorectal cancer was not statistically significant in this study. There was no significant link found for prostate, rectal, pancreatic, or brain cancers.

In individuals with type 2 diabetes and obesity, treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) does not increase the risk of suicidal ideation or self-injury (SIS) compared to sodium-glucose cotransporter 2 inhibitors (SGLT-2i).

If you have type 2 diabetes and obesity, current evidence suggests that GLP-1RA medications do not increase your risk of suicidal thoughts or self-harm compared to other common diabetes drugs like SGLT-2 inhibitors. While regulators are reviewing safety data based on early reports, this large study found no such link. However, because these events are rare, the possibility of a small increased risk cannot be completely excluded, so monitoring your mental health remains important.